CD8A and neoplasm: Immune checkpoint blockade antibodies, such as anti-CTLA-4, anti-PD-1, or anti-TIGIT, were tested to deplete T-regs since they are upregulated both on CD8 T-cells and T-regs in tumors, enhancing anti-tumor T-cell functions while simultaneously disabling T-regs to potently enhance the liver cancer immune response [134].